Applying novel methods to assess clinical outcomes: Insights from the TRILOGY ACS trial

European Heart Journal

Volumn 36, Issue 6, 2015, Pages 385-392

  Bakal, Jeffrey A ^a   Roe, Matthew T ^b   Ohman, E Magnus ^b   Goodman, Shaun G ^a,c   Fox, Keith A A ^d   Zheng, Yinggan ^a   Westerhout, Cynthia M ^a   Hochman, Judith S ^e   Lokhnygina, Yuliya ^b   Brown, Eileen B ^f   Armstrong, Paul W ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f ELI LILLY AND COMPANY   (United States)

Author keywords

Acute coronary syndromes; Clinical trial; Composite endpoints

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PRASUGREL; ANTITHROMBOCYTIC AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ANALYTIC METHOD; ARTICLE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DEATH; FOLLOW UP; HAZARD RATIO; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; METHODOLOGY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PRODUCTIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SURVIVAL; UNSTABLE ANGINA PECTORIS; AGED; ANALOGS AND DERIVATIVES; ANGINA, UNSTABLE; BIOASSAY; CLINICAL TRIAL; CONTROLLED STUDY; MIDDLE AGED; MULTICENTER STUDY; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; STROKE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

AGED; ANGINA, UNSTABLE; ENDPOINT DETERMINATION; HUMANS; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PRASUGREL HYDROCHLORIDE; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECURRENCE; STROKE; SURVIVAL ANALYSIS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84928266975     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehu262     Document Type: Article

References (13)

1. Claggett B,Wei LJ, Pfeffer MA. Moving beyond our comfort zone. Eur Heart J 2013; 34:869-871.
2. Subherwal S, Anstrom KJ, Jones WS, Felker MG, Misra S, Conte MS, Hiatt WR, Patel MR. Use of alternative methodologies for evaluation of composite end points in trials of therapies for critical limb ischemia. Am Heart J 2012;164:277-284.
3. Pocock SJ, Ariti CA, Collier TJ,Wang D. The win ratio: a newapproach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur Heart J 2012; 33:176-182.
4. Bakal JA, Westerhout CM, Cantor WJ, Fernández-Avilés F, Welsh RC, Fitchett D, Goodman SG, ArmstrongPW. Evaluation of early percutaneous coronary intervention vs. standard therapy after fibrinolysis for ST-segment elevation myocardial infarction: contribution of weighting the composite endpoint. Eur Heart J 2013;34: 903-908.
5. Chin CT, Roe MT, Fox KA, Prabhakaran D, Marshall DA, Petitjean H, Lokhnygina Y, Brown E, Armstrong PW, White HD, Ohman EM on behalf of the TRILOGY ACS Steering Committee. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. Am Heart J 2010;160:16-22.
6. Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, Cornel JH, Bhatt DL, Clemmensen P, Martinez F, Ardissino D, Nicolau JC, Boden WE, Gurbel PA, Ruzyllo W, Dalby AJ, McGuire DK, Leiva-Pons JL, Parkhomenko A, Gottlieb S, Topacio GO, Hamm C, Pavlides G, Goudev AR, Oto A, Tseng CD, Merkely B, Gasparovic V, Corbalan R, Cinteza? M, McLendon RC, Winters KJ, Brown EB, Lokhnygina Y, Aylward PE, Huber K, Hochman JS, Ohman EM for the TRILOGY ACS Investigators. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 2012;367:1297-1309.
7. Andersen PK, Gill RD. Cox's regression model for counting processes: a large sample study. Ann Statistics 1982;10:1100-1120.
8. Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, Goodman SG, Granger CB, Steg G, Gore JM, Budaj A, Avezum A, Flather MD, Fox KAA. for the GRACE Investigators. A validated prediction model for all forms of acute coronary syndrome: Estimating the Risk of 6-Month Postdischarge Death in an International Registry. JAMA 2004;291:2727-2733.
9. ArmstrongPW,Westerhout CM, Van deWerf F, Califf RM,Welsh RC, Wilcox RG, Bakal JA. Refining clinical trial composite outcomes: an application to the Assessment of the Safety and Efficacy of a New Thrombolytic-3 (ASSENT-3) trial. Am Heart J 2011;161:848-854.
10. Bakal JA,WesterhoutCM,ArmstrongPW. Impact of weighted composite compared to traditional composite endpoints for the design of randomized controlled trials. Stat Methods Med Res 2012. doi: 10.1177/0962280211436004.
11. Metcalfe C, Thompson SG. The importance of varying the event generation process in simulation studies of statistical methods for recurrent events. Statist Med 2006;25: 165-179.
12. Wei LJ, Lin DY, Weissfeld L. Regression-analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Statist Assoc 1989;84: 1065-1073.
13. Borgia F, Goodman SG, Halvorsen S, Cantor WJ, Piscione F, Le May MR, Fernandez-Aviles F, Sanchez PL, Dimopoulos K, Scheller B, Armstrong PW, Di Mario C. Early routine percutaneous coronary intervention after fibrinolysis vs.: standard therapy in ST-segment elevation myocardial infarction: a meta-analysis. Eur Heart J 2010;31:2156-2169.